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Objective. To examine the tolerability and antitumor activity of trebananib plus pegylated liposomal doxoru-
bicin (PLD) or topotecan in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Methods. In this open-label phase 1b study, patients received trebananib 10 mg/kg or 15 mg/kg IV QW plus
PLD 50 mg/m2 (cohorts A1 and A3, respectively) or topotecan 4 mg/m2 (cohorts B1 and B3, respectively). End-
points were dose-limiting toxicity (DLT; primary); treatment-emergent adverse events (AEs), overall response
rate, anti-trebananib antibodies, and pharmacokinetics (secondary).
Results. 103 patients were enrolled. One patient in A1 and B1 had DLTs. Across all cohorts, themost common
AEs were nausea, fatigue, and peripheral edema. Across both trebananib plus PLD cohorts (A1/A3), grade 4 AEs
were pulmonary embolism, disease progression, and anemia. Two patients had grade 5 intestinal perforation
(n = 1) and sudden death (n = 1). Across both trebananib plus topotecan cohorts (B1/B3), grade 4 AEs were
neutropenia, hypokalemia, decreased granulocyte count, chest pain, dyspnea, decreased neutrophil count, and
pulmonary embolism. Two patients had grade 5 disease progression. One patient had grade 5 pleural effusion as-
sociated with progressive disease. Conﬁrmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1),
and 0.0% (B3). Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1
(B3), respectively. No drug–drug interactions were apparent.ot been previously published or submitted for publication elsewhere. The resultswerepresented inpart at the Clinical Oncology
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26 I. Vergote et al. / Gynecologic Oncology 135 (2014) 25–33Conclusions. Trebananib 10 mg/kg and 15 mg/kg IV QWplus PLD or topotecan appear to have acceptable tox-
icity proﬁles in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Antitumor activity
was evident across all cohorts.
© 2014 Elsevier Inc. All rights reserved.Introduction
Although patients with ovarian cancer generally respond to initial
platinum-based chemotherapy, most patients will experience disease
progression [1]. Patients whose disease recurs N12 months after com-
pletion of ﬁrst-line platinum treatment tend to respond to reinduction
platinum therapy (i.e., platinum-sensitive disease) and have a favorable
prognosis [2]. In contrast, patients who relapse within one year after
treatment with a platinum agent are generally less responsive to
reinduction platinum therapy. Those patients are considered as having
either platinum-resistant disease (i.e., disease recurrence b6 months
after last platinum dose) or partially platinum-sensitive disease (i.e., dis-
ease recurrence 6 to 12 months after last platinumdose). For both groups
of patients, standard second-line treatment can involve nonplatinum
agents [3–5]. For patients with platinum-resistant disease, pegylated li-
posomal doxorubicin (PLD) and topotecan are currently FDA- and
EMA-approved treatment agents. However, those treatments are not
curative and largely considered as palliative. In patients with platinum-
resistant diseasewho are treatedwith PLD and topotecan, 3-year survival
rates have been found to be 13.8% and 9.5%, respectively [5]. For patients
with partially platinum-sensitive disease, treatment with nonplatinum
agents – such as PLD or topotecan – can be considered in order to extend
the platinum-free interval and possibly increase the likelihood of a suc-
cessful platinum retreatment at a later relapse [6].
To further extend the efﬁcacy of second-line treatments in patients
with suboptimal platinum-free intervals, clinical research has begun to
examine the addition of targeted therapies to second-line chemothera-
py regimens. Targeting angiogenesis, the process of new blood vessel
formation that is required for solid tumor growth andmetastatic spread,
has been of particular interest [7]. To date, studies of angiogenic inhibi-
tors have focused almost exclusively on treatments involving vascular
endothelial growth factor (VEGF) pathway inhibitors combined with
chemotherapy agents. Those combination treatments can provide clin-
ical beneﬁts in the platinum-resistant recurrent setting, although it is
not clear yet whether those beneﬁts translate into longer overall surviv-
al rates. In a phase 3 study of patients receiving bevacizumab combined
with PLD, topotecan, or paclitaxel, the primary endpoint of improved
progression-free survival (PFS) was met in patients receiving the com-
bination compared with those receiving only PLD, topotecan, or pacli-
taxel [8]. However, a follow-up analysis did not detect a statistically
signiﬁcant difference in overall survival between the two patient groups
[9]. In a phase 1/2 study of the VEGF receptor inhibitor vandetanib
combinedwith PLD, the treatmentwas associatedwith antitumor activ-
ity, but was deemed intolerable because of the emergence of severe
toxicities [10].
The angiopoietin axis is distinct from the VEGF pathway and critical
to angiogenesis [7,11,12]. Angiopoietin-1 (Ang1) and angiopoietin-2
(Ang2) are endogenous ligands which bind to Tie2, a tyrosine kinase
receptor expressed primarily on the vascular endothelium [13]. Ang1
contributes to vessel stabilization andmaturationwhile Ang2 drives ves-
sel destabilization and new vessel sprouting [13,14]. Trebananib is an
investigational peptide–Fc fusion protein (“peptibody”) that is adminis-
tered intravenously (IV) and inhibits tumor angiogenesis by binding to
Ang1 and Ang2, thereby blocking their interactions with the Tie2 recep-
tor [14]. Preclinical xenograft models demonstrated that dual inhibition
of Ang1 and Ang2, as achieved with trebananib, results in greater
tumor suppression relative to inhibition of Ang1 or Ang2 in isolation
[15]. In a ﬁrst-in-human monotherapy study of patients with advanced
solid tumors, trebananib exhibited a distinct toxicity proﬁle and demon-
strated antitumor activity [16]. One patient with refractory ovariancancer in that study had a tumor reduction of 32.5% and a conﬁrmed
partial response (PR) at week 72; the patient withdrew from the study
with a PR after 156 weeks of treatment. A phase 2 study suggested that
patients with recurrent ovarian cancer receiving trebananib 3 mg/kg
or 10 mg/kg once a week (QW) plus paclitaxel experienced longer
PFS than patients receiving placebo QW plus paclitaxel [17]. In the ran-
domized double-blind phase 3 TRINOVA-1 study, weekly trebananib
15 mg/kg combined with paclitaxel signiﬁcantly improved PFS com-
pared toweekly placebo combinedwith paclitaxel [18]. The combination
of trebananib and PLD in patients with recurrent platinum-resistant or
partially platinum-sensitive ovarian cancer is currently under investiga-
tion in a phase 3 study (TRINOVA-2/ENGOT-ov6).
PLD and topotecan are FDA-approved chemotherapies for recurrent
ovarian cancer [5,19]. Since trebananib blocks uniquemolecular targets,
the addition of trebananib to PLD or topotecanwas expected to improve
efﬁcacy without exacerbating known toxicities associated with PLD or
topotecan monotherapy. Therefore, the objectives of the current study
were to examine the tolerability and antitumor activity of trebananib
plus PLD or topotecan in patients with recurrent ovarian cancer.
Methods
Patients
All women (≥18 years old) had radiographically documented pro-
gression of recurrent, invasive epithelial ovarian, fallopian tube, or pri-
mary peritoneal cancer per Response Evaluation Criteria in Solid
Tumors, version 1.0 (RECIST, v1.0) or CA-125 progression per Gyneco-
logic Cancer Intergroup (GCIG) guidelines [20,21]. Other eligibility
criteria included: patients had a Gynecologic Oncology Group (GOG)
performance status≤1, and a history of fewer than four anticancer ther-
apies and at least one platinum-based regimen. Patients were excluded
if they had a priormalignancy, unless the patientwas treatedwith cura-
tive intent, did not exhibit the disease during the 3 years before enroll-
ing in the study, and was considered to be at low risk for recurrence by
the treating physician. Patients with nonmelanomatous skin cancer,
lentigo maligna, or cervical carcinoma in situ who were adequately
treated and did not show any evidence of disease were also eligible to
enroll. Additional exclusion criteria included a higher-than-average
risk of bowel perforation (i.e., symptoms or a recent history of ﬁstula
or bowel obstruction, or a need for parenteral nutrition or continuous
hydration), a known history of central nervous system metastases, or
arterial or deep venous thromboembolism during the year prior to
enrollment. Patients were also excluded from study enrollment if they
had prior treatment with abdominal or pelvic external beam radiothera-
py,myeloablative high-dose chemotherapywith allogeneic or autologous
stem cell transplant, or recent treatment with immune modulators. Pa-
tients previously treated with PLD or doxorubicin were excluded from
the PLD cohorts; patients who previously received topotecan were ex-
cluded from the topotecan cohorts. All patients provided written in-
formed consent. Study procedures were performed after approval by
independent institutional reviewboards and in accordancewith an assur-
ance ﬁled with and approved by the Department of Health and Human
Services.
Study design and treatment
This 2-part open-label, dose-escalation/de-escalation phase 1b study
was carried out across 13 international centers. The primary endpoint
was the patient incidence of dose-limiting toxicities (DLTs). Secondary
Table 1
Baseline demographics and disease characteristics.a
Cohort A1 Cohort A3 Cohort B1 Cohort B3
Trebananib Trebananib Trebananib Trebananib
10 mg/kg 15 mg/kg 10 mg/kg 15 mg/kg
+ PLD + PLD + topotecan + topotecan
(N = 25) (N = 27) (N = 25) (N = 26)
Race/ethnicity, n (%)
White or Caucasian 21 (84) 25 (93) 24 (96) 24 (92)
Black or African American 3 (12) 2 (7) 0 (0) 1 (4)
Hispanic 0 (0) 0 (0) 1 (4) 1 (4)
Asian 1 (4) 0 (0) 0 (0) 0 (0)
Age, median (range), years 56 (36–73) 55 (34–81) 59 (46–78) 59 (28–75)
GOG performance score, n (%)
0 17 (68) 17 (63) 18 (72) 13 (50)
1 8 (32) 10 (37) 7 (28) 13 (50)
Tumor histology, n (%)
Serous 17 (68) 23 (85) 13 (52) 19 (73)
Endometrioid 0 (0) 3 (11) 4 (16) 3 (12)
Clear cell 0 (0) 0 (0) 1 (4) 3 (12)
Mucinous 0 (0) 0 (0) 2 (8) 0 (0)
Unclassiﬁed 5 (20) 1 (4) 5 (20) 1 (4)
Not available 3 (12) 0 (0) 0 (0) 0 (0)
FIGO disease stage at screening, n (%)
I 0 (0) 1 (4) 0 (0) 0 (0)
II 0 (0) 0 (0) 1 (4) 1 (4)
III 14 (56) 13 (48) 10 (40) 9 (35)
IV 10 (40) 13 (48) 12 (48) 14 (54)
Unknown 1 (4) 0 (0) 2 (8) 2 (8)
Number of lines of prior anticancer therapy, n (%)
1 10 (40) 11 (41) 10 (40) 7 (27)
2 9 (36) 12 (44) 6 (24) 12 (46)
3 6 (24) 4 (15) 9 (36) 7 (27)
Number of lines of prior platinum therapy, n (%)
1 16 (64) 13 (48) 16 (64) 14 (54)
2 7 (28) 14 (52) 9 (36) 9 (35)
3 2 (8) 0 (0) 0 (0) 3 (12)
Prior PLD or doxorubicin therapy, n (%) 0 (0) 0 (0) 12 (48) 13 (50)
Prior topotecan therapy, n (%) 1 (4) 0 (0) 0 (0) 0 (0)
Platinum sensitivity status, n (%)b
Primary platinum refractory (PFI b6 months) 0 (0) 1 (4) 2 (8) 2 (8)
Platinum-resistant (PFI b6 months) 21 (84) 18 (67) 17 (68) 14 (54)
Partially platinum-sensitive (PFI 6–12 months) 3 (12) 7 (26) 4 (16) 4 (15)
Platinum-sensitive (PFI N12 months) 1 (4) 0 (0) 1 (4) 3 (12)
Not available 0 (0) 1 (4) 1 (4) 3 (12)
Number of trebananib dosing cycles, median (range) 5.0 (1.0–18.0) 6.0 (2.0–15.0) 4.0 (1.0–35.0) 3.5 (1.0–17.0)
Relative trebananib dose intensity,c mean (SD) 0.810 (0.108) 0.808 (0.107) 0.773 (0.153) 0.811 (0.060)
Number of trebananib doses withheld, n (%) 69 (13) 54 (10) 37 (6) 44 (12)
Number of PLD dose changes, n (%) 64 (42) 60 (47) NA NA
Number of topotecan dose changes, n (%) NA NA 106 (28) 45 (16)
Follow-up time, median (range),d weeks 31 (4–78) 28 (0–61) 23 (9–144) 20 (0–74)
FIGO, International Federation of Gynecology andObstetrics; GOG,Gynecologic OncologyGroup; PLD, pegylated liposomal doxorubicin; PFI, platinum-free interval; NA, not applicable; SD,
standard deviation.
a The analyses were conducted with all enrolled patients in this study.
b The deﬁnition of platinum-refractory disease was based on the time to progression from the ﬁrst dose of the ﬁrst platinum regimen and was at most 182 days. This deﬁnition differs
from the alternative deﬁnition of time to progression from the last dose of the last platinum regimen and is at most 28 days. The remaining platinum sensitivity categories were based on
the time to progression from the last dose of the last platinum regimen.
c Relative dose intensity is the ratio of the actual cumulative trebananib dose relative to the protocol-speciﬁed cumulative trebananib dose up to study treatment discontinuation.
d Follow-up time is calculated from the date of enrollment to the date of the last study visit.
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jective response rate (ORR), PFS, CA-125 response, patient incidence
of anti-trebananib antibody formation, and pharmacokinetic (PK) pro-
ﬁles. Changes in biomarkers were an exploratory endpoint. Patients re-
ceived trebananib 10 mg/kg or 15 mg/kg IV QW plus PLD 50 mg/m2 IV
every 4 weeks (Q4W; cohorts A1 and A3, respectively), or trebananib
10 mg/kg or 15 mg/kg IV QW plus topotecan 4 mg/m2 IV (cohorts B1
and B3, respectively). Topotecan in cohorts B1 and B3was administered
on days 1, 8, and 15 of a 28-day schedule. The original study design also
included dose de-escalation cohorts of trebananib 3 mg/kg plus PLD or
topotecan (cohorts A2 and B2, respectively) whichwere to be opened if
trebananib 10 mg/kgwere to bedetermined to be intolerable. Those co-
horts were not initiated because of the low incidence of DLTs in cohortsreceiving trebananib 10 mg/kg plus PLD or topotecan (cohorts A1 and B1,
respectively). Instead, cohorts receiving trebananib 15 mg/kg plus PLD or
topotecan (cohorts A3 and B3, respectively) were added. Trebananib was
discontinued if dosingwaswithheld for N28 days. Trebananib dose levels
were based on a ﬁrst-in-human study that found trebananibmonothera-
py to be tolerable up to 30 mg/kg [16]. PLD dosing followed FDA-ap-
proved dosing guidelines. Weekly topotecan administration has been
favored over FDA-approveddaily dosing to attempt tominimize toxicities
[22,23]. Dose modiﬁcations for PLD and topotecan are described in the
Supplementary material section.
Patient enrollment is described in the Supplementary material sec-
tion. All patients who received at least one dose of trebananib plus PLD
or topotecan were included in all safety analyses, including DLT analyses
Table 2
Patient incidence of treatment-emergent adverse events by grade.a
Cohort A1 Cohort A3 Cohort B1 Cohort B3
Trebananib Trebananib Trebananib Trebananib
10 mg/kg 15 mg/kg 10 mg/kg 15 mg/kg
+ PLD + PLD + topotecan + topotecan
(N = 25) (N = 25) (N = 25) (N = 24)
Patients with any adverse event, n (%) 25 (100) 25 (100) 25 (100) 24 (100)
Grade 1 1 (4) 0 (0) 1 (4) 1 (4)
Grade 2 3 (12) 4 (16) 7 (28) 6 (25)
Grade 3 19 (76) 17 (68) 13 (52) 12 (50)
Grade 4 1 (4)b 3 (12)c 4 (16)d 2 (8)e
Grade 5 1 (4)f 1 (4)g 0 (0) 3 (13)h
PLD, pegylated liposomal doxorubicin.
a All patients who received at least one dose of trebananib plus its cotherapy were evaluated for adverse events. Treatment-emergent adverse events included all adverse events that
were recorded during study treatment and within 30 days of the last dose of any treatment agent.
b One patient had grade 4 disease progression.
c Three patients had grade 4 adverse events of pulmonary embolism (n = 2 [8%]) and anemia (n = 1 [4%]).
d Four patients with grade 4 adverse events had neutropenia (n = 2 [8%]), hypokalemia (n = 1 [4%]), decreased granulocyte count (n = 1 [4%]), chest pain (n = 1 [4%]), and dyspnea
(n = 1 [4%]).
e Two patients with grade 4 adverse events had decreased neutrophil count (n = 1 [4%]) and pulmonary embolism (n = 1 [4%]).
f One patient had a grade 5 adverse event of intestinal perforation, which was not considered by the investigator to be related to trebananib or PLD treatment.
g This patient had a grade 5 adverse event of sudden death. No autopsy was performed, and the cause of death is unknown. The death was not considered by the investigator to be
related to trebananib or PLD treatment.
h Three patients died of disease progression (n = 2 [8%]) and pleural effusion (n = 1 [4%]). Those deaths were not considered by the investigator to be related to trebananib or
topotecan treatment.




































Grade ≥3 AEs occurring in ≥10% of patients in
cohort A1 or A3
AEs of interesta
AEs occurring in ≥20% of patients in
cohort A1 or A3
Cohort A1: Trebananib 10 mg/kg + PLD (n = 25) Cohort A3: Trebananib 15 mg/kg + PLD (n = 25)
a No patient in either cohort developed arterial thromboembolic events, hemorrhage, impaired wound healing, or infusion-related
reactions.











Fig. 1. Patient incidence of treatment-emergent adverse events (AEs) in the trebananib plus PLD cohorts. All patients who received at least one dose of trebananib plus its cotherapywere
evaluated for AEs. Treatment-emergent adverse events AEs included all adverse events AEs thatwere recordedduring study treatment andwithin 30 days of the last dose of any treatment
agent.
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Table 3
Summary of trebananib pharmacokinetic parameters.
Descriptive statistic Cmax AUCtau CL Vss Cmin
(μg/mL) (mg•h/mL) (mL/h/kg) (mL/kg) (μg/mL)
Cohort A1: trebananib 10 mg/kg + PLD
n 16 14 14 14 13
Mean 263 9.15 1.20 57.8 20.0
SD 59.2 2.93 0.370 16.9 12.1
Median 254 8.52 1.18 55.4 16.3
%CV 22.5 32.0 30.8 29.2 60.6
Cohort A3: trebananib 15 mg/kg + PLD
n 19 18 18 18 17
Mean 352 11.9 1.41 67.6 26.0
SD 113 4.55 0.488 21.2 15.7
Median 330 9.69 1.56 67.9 21.2
%CV 32.1 38.2 34.7 31.4 60.6
Cohort B1: trebananib 10 mg/kg + topotecan
n 17 16 16 16 15
Mean 242 9.06 1.20 61.9 20.8
SD 86.3 2.86 0.406 21.4 7.06
Median 213 8.59 1.14 60.0 19.8
%CV 35.7 31.6 33.8 34.5 33.9
Cohort B3: trebananib 15 mg/kg + topotecan
n 20 16 16 16 14
Mean 352 12.7 1.33 60.0 29.2
SD 95.9 4.25 0.545 15.5 13.5
Median 336 12.7 1.14 61.9 27.1
%CV 27.2 33.4 41.0 25.8 46.2
Cmax, maximum observed concentration after intravenous infusion of trebananib; AUCtau,
area under the concentration–time curve from time zero to 168 h; CL, serum clearance
after intravenous infusion; Vss, volume of distribution at steady state; Cmin, minimum ob-
served concentration (trough concentration); %CV, coefﬁcient of variation, expressed as a
percent; SD, standard deviation; PLD, pegylated liposomal doxorubicin.
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grade≥3 AE per Common Terminology Criteria for Adverse Events, ver-
sion 3.0 (CTCAE, v3.0) and related to trebananib treatment. The following
AEs were not considered DLTs: grade 3 anemia, hypertension, or throm-
bocytopenia; grade 3 fatigue or grade 4 neutropenia lasting ≤7 days;
grade 3 or 4 diarrhea, nausea, or vomiting lasting ≤72 h; grade 3 or 4
neutropenia with fever ≤38.5 °C; and aspartate or alanine aminotrans-
ferase less than 10 times the upper limit of normal.Adverse events
Unless otherwise noted, this report presents treatment-emergent AEs
occurring after study treatment initiation up to 30 days after the last dose
of any study drug and recorded per CTCAE, v3.0.Tumor response assessments
Computed tomography (CT) or magnetic resonance imaging (MRI)
per RECIST v1.0 was conducted every 8 weeks during the ﬁrst 2 years
and every 6 ± 1 months thereafter or until progression. ORR was
assessed in patients with at least one measurable lesion per modiﬁed
RECIST v1.0. A complete response or PR required a conﬁrmatory evalu-
ation ≥28 days after the initial assessment. The analyses of progressive
diseasewere based onmodiﬁed RECIST v1.0, clinical or CA-125 progres-
sion, or death, and included all patients who received at least one dose
of trebananib plus PLD or topotecan. For ORR and PFS analyses, RECIST
was modiﬁed to include only radiographic imaging. Only imaging of
the chest, pelvis, and abdomen was required. However, head lesions
were followed up with CT or MRI assessments to conﬁrm progression
per RECIST. CA-125 responses were evaluated every 4 ± 1 weeks,
with a conﬁrmatory assessment ≥28 days after the initial assessment.Clinical immunology
Immunogenicity of trebananib was evaluated via serum samples
that were collected immediately before administration of trebananib,
PLD, and topotecan at weeks 1, 5, 9, and every 16 weeks thereafter,
and at the safety follow-up visit. The methodology for evaluating anti-
bodies has been previously described [24].
Pharmacokinetics
Serum trebananib concentrations were measured using an enzyme-
linked immunosorbent assay [16]. Plasma concentrations of PLD,
doxorubicinol, topotecan, and topotecan lactone were evaluated with
validated high-performance liquid chromatography (HPLC) methods.
The schedule of PK assessments is detailed in the Supplementary mate-
rial section. Noncompartmental analyses of PK parameters were con-
ducted with WinNonlin Enterprise software, version 5.1.1 (Pharsight
Corporation, Mountain View, CA, USA).
Pharmacodynamics
Angiogenic biomarkers from serum included soluble vascular cell ad-
hesion molecule-1 (sVCAM-1), placental growth factor (PLGF), VEGF,
soluble fms-like tyrosine kinase-1 (VEGFR-1), soluble KDR (VEGFR-2),
soluble c-Kit (sKit), Ang1, Ang2, and soluble intercellular adhesion mol-
ecule-1 (slCAM-1). The methodology for assessing angiogenic bio-
markers has been previously described [25]. The assays for Ang1 and
Ang2measured free and trebananib-bound angiopoietins and, therefore,
were implemented only for predose samples. The schedule for collecting
blood samples is described in the Supplementary material section.
Statistical analysis
Descriptive statistics were implemented to describe the tolerability,
ORR, CA-125 response, and antibody formation. Kaplan–Meier esti-
mates of median PFS were based on the deﬁnition of disease progres-
sion per modiﬁed RECIST v1.0, clinical, or CA-125 criteria. Statistical
signiﬁcance for pharmacodynamic responses was determined with
an F-test comparing log-transformed analyte and baseline values.
The study was not designed to compare endpoints between study co-
horts. All protocol-deﬁned statistical analyseswere described in the sta-




Between January 2009 andOctober 2011, 103 patientswere enrolled.
Most patients had serous tumor histology and International Federation
of Gynecology and Obstetrics (FIGO) stage III or IV disease. More than a
third of patients had received at least twoplatinum-containing regimens.
The majority of patients experienced disease progression ≤6 months
after their last platinum-based therapy. Baseline demographic and dis-
ease characteristics are summarized in Table 1.
Toxicity
A total of 99 patients were included in the DLT analysis set (cohorts
A1, A3, B1, B3; n = 25, 25, 25, 24). No DLTs occurred during the initial
phase. During the expansion phase, one patient (4%) in cohort A1 devel-
oped DLTs of grade 3 appendiceal abscess and appendicitis. A DLT of
grade 3 peripheral edema occurred in one patient (4%) in cohort B1.
Unless noted otherwise, this report summarizes treatment-emer-
gent AEs occurring between study treatment initiation and 30 days
after the last does of any study drug (Fig. 1 and 2). All patients had at
Grade ≥ 3 AEs occurring in ≥10% of patients in
cohort B1 or B3
AEs of interesta
AEs occurring in ≥20% of patients in
cohort B1 or B3
Cohort B1: Trebananib 10 mg/kg + topotecan (n = 25) Cohort B3: Trebananib 15 mg/kg + topotecan (n = 24)







































n = n =
n =
a No patient in either cohort developed arterial thromboembolic events, blurred vision, gastrointestinal perforation, hypertension,
or impaired wound healing.
Fig. 2. Patient incidence of treatment-emergent adverse events (AEs) in the trebananib plus topotecan cohorts. All patients who received at least one dose of trebananib plus its cotherapy
were evaluated for AEs. Treatment-emergent AEs included all AEs that were recorded during study treatment and within 30 days of the last dose of any treatment agent.
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A3), serious AEs occurred in 26 patients (52%). A grade 4 AE of pulmo-
nary embolism in a patient (4%) in cohort A3 was considered by the in-
vestigator as possibly related to trebananib treatment. One patient (4%)
in cohort A1 had a grade 5 intestinal perforation and died after develop-
ing bowel obstruction; this patient died 20 days after receiving the last
dose of any study agent. The investigator rated the death as unrelated to
trebananib or PLD and reported the cause of the perforation as growth
of tumor in transversum, ischemic basis, or colon dilation. Treatment
for the event included piperacillin and tazobactam sodium, sodium in-
fusion, and morphine. Because of the patient's poor prognosis, she re-
ceived conservative treatment. One patient (4%) in cohort A3 had a
grade 5 AE of sudden death and died of unknown causes 2 days after
the last dose of any study agent was administered. This death also was
not considered by the investigator to be related to trebananib or PLD
treatment. Across both trebananib plus topotecan cohorts (B1 and B3),
18 patients (37%) developed serious AEs. One patient (4%) in cohort
B1 experienced a grade 4 decreased granulocyte count, which was con-
sidered by the investigator as possibly related to trebananib and
topotecan treatments. Two patients (8%) in cohort B3 died of disease
progression 24 and 30 days after receiving the last dose of any study
drug. One patient (4%) in cohort B3 had a grade 5 pleural effusion associ-
ated with progressive disease 19 days after the last study drug adminis-
tration. Those deaths were not considered by the investigator to be
related to trebananib or topotecan treatment.
Grade≥3 AEs of interest that were considered by the investigator as
possibly related to trebananib treatment across cohorts A1 and A3were
peripheral edema (n= 4 [8%]), venous thromboembolic events (n = 3[6%]), hemorrhages (n = 1 [2%]), ascites (n = 1 [2%]), gastrointestinal
perforation (n=2 [4%]), hypokalemia (n=1 [2%]), andpleural effusion
(n= 1 [2%]). Across cohorts B1 and B3, those criteria applied to periph-
eral edema (n= 3 [6%]) and hypokalemia (n= 1 [2%]). The AEs of gas-
trointestinal perforation related to trebananib administration in cohorts
A1 and A3 occurred in a patient who developed gastric ulcer perforation
8 months after trebananib initiation; the other patient developed an
appendiceal abscess oneweek after trebananib initiation,which resolved
11 days later. All AEs of hypertension occurred in cohorts A1 and A3 and
were grade ≤2. Among those, no patient had the disease as a pre-
existing condition. For four patients (8%), hypertension was considered
as possibly related to trebananib treatment.Tumor response
Tumor response was evaluated in all patients with at least one mea-
surable lesion per modiﬁed RECIST v1.0 (Table S1 in the Supplementary
material section). Conﬁrmed ORRs in cohorts A1, A3, B1, and B3 were
36.0%, 34.8%, 16.7%, and 0.0%, respectively. Tumor size decreased by ame-
dian of 18.9%, 28.2%, 2.4%, and 13.9% in cohorts A1, A3, B1, and B3, respec-
tively. Median PFS (95% CI) in cohorts A1, A3, B1, and B3 was 7.4 months
(2.5–7.8 months), 7.1 months (3.4–8.1 months), 3.5 months (1.7–
5.1 months), and 3.1 months (1.8–5.3 months), respectively (Fig. S1A
and B in the Supplementary material section). In CA-125 evaluable pa-
tients, 10 (47.6%) of 21 patients in cohort A1, 10 (55.6%) of 18 patients
in cohort A3, 8 (34.8%) of 23 patients in cohort B1, and 7 (38.9%) of 18 pa-
tients in cohort B3 had a conﬁrmed CA-125 response.
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Evaluable postdose samples for testing of anti-trebananib antibodies
were available for 49 patients across cohorts A1 and A3, and 47 patients
across cohorts B1 and B3. One patient (4%) in cohort B1 had pre-existing
anti-trebananib binding antibodies. Two patients (8%) in cohort A3, one
patient (4%) in cohort B1, and one patient (4.5%) in cohort B3 developed
anti-trebananib binding antibodies during study treatment. The patient
in cohort B3 continued to test positive at treatment termination. The
presence of anti-trebananib binding antibodies did not appear to affect
trebananib PK (data not shown here). No neutralizing antibodies were
detected.
Pharmacokinetics
The mean serum concentration–time proﬁles after four weekly infu-
sions of trebananib 10 mg/kg when coadministered with PLD or
topotecan were similar to those reported in the ﬁrst-in-human mono-
therapy study (Table 3) [16]. No drug–drug interactions were apparent
between trebananib 10 mg/kg or 15 mg/kg and PLD or topotecan and
their metabolic byproducts (Fig. 3A–D).
Pharmacodynamics
Serum samples for pharmacodynamic analyseswere available for 93
patients. Pharmacodynamic changes relative to baseline occurred in
sVCAM-1, which peaked 24 to 48 h after trebananib administration
across cohorts (Fig. S2 in the Supplementary material section). Baseline
levels of VEGF correlated with PFS when the population was divided at
the median VEGF level (595 ng/mL; HR= 2.09 [95% CI, 1.22–3.59; p =
0.007]); patients with lower baseline VEGF had longer PFS. Baseline
levels of Ang2 correlated with PFS when the population was divided
at the median Ang2 level (2440 pg/mL; HR = 2.04 [95% CI, 1.17–3.56;
p= 0.011]); patientswith lower Ang2 had longer PFS. The study design
did not allow for an evaluation of the predictive or prognostic value of
these markers.
Discussion
Single-agent treatment with PLD or topotecan is currently a treat-
ment option for patients with platinum-resistant or partially platinum-
sensitive recurrent ovarian cancer.While both treatments are considered
to provide equal or improved efﬁcacy relative to other chemotherapy
agents, the clinical beneﬁts of either treatment are modest. In patients
with platinum-resistant disease, PLD monotherapy has been associated
with response rates of 8.3% to 16% and PFS of 2.3 to 4.0 months [3,5,26,
27]. In patients receiving weekly topotecan, results from a phase 2
study suggest a response rate of 22% and PFS of 4.2 months [22]. PLD
or topotecan is often selected as the preferred treatment for platinum-
resistant disease because treatment is focused on palliation of symp-
toms and the toxicities of both agents are considered relatively
moderate. Although the efﬁcacy of PLD or topotecan treatment is
generally improved in patients with partially platinum-sensitive
disease relative to those with platinum-resistant disease, the re-
sponse rates for patients with partially platinum-sensitive disease
are approximately 25%–30% [2,28,29]. The results of this study suggest
that the addition of trebananib 10 mg/kg and 15 mg/kg to PLD or
topotecan may provide an alternative treatment approach. The treat-
ment combinations tested in this studywere associatedwith acceptable
toxicity proﬁles. Combining an antiangiogenic agent and chemotherapy
has the potential risk of synergistic toxic effects [30,31]. In this study,
toxicities were generally consistent with those that have been associat-
ed with monotherapy of trebananib, PLD, or topotecan [16,32,33]. Pe-
ripheral edema has been previously identiﬁed as a risk associated
with trebananib treatment and generally manageable across studies
[16,17,34,35]. Other AEs that have been associated with trebananib incombination with chemotherapy are ascites and pleural effusion [35].
More recently, blurred vision was identiﬁed as a risk associated with
trebananib administration. The incidence of ascites and pleural effusion
appeared largely consistent with results from the randomized phase 3
TRINOVA-1 study of patients with recurrent platinum-resistant or par-
tially platinum-sensitive ovarian cancer receiving trebananib 15 mg/kg
plus paclitaxel [36]. All AEs of blurred vision weremild andmanageable.
Palmar–plantar erythrodysesthesia and stomatitis are toxicities that
emerge typically with PLD treatment. The incidence rates of both AEs
in the cohorts receiving trebananib plus PLDwere consistentwith results
from an earlier phase 3 study investigating PLD monotherapy, although
direct comparisons cannot be made given that the present investigation
was a phase 1 study [26]. In the earlier study, hematological toxicities, in-
cluding neutropenia, anemia, thrombocytopenia, and leukopenia, were
identiﬁed as AEs associatedwith topotecan treatment. Those hematolog-
ical AEs also emerged in the current study in the cohorts receiving
trebananib plus topotecan. However, there was no evidence to suggest
that the addition of trebananib to topotecan exacerbated the severity of
such toxicities.
In this study, no patient developed arterial thromboembolic events or
impaired wound healing. Hypertension occurred only in the trebananib
plus PLD cohorts (A1 and A3); all were grade ≤2 and manageable. The
incidence of hypertensionwas slightly higher compared to earlier studies
of trebananib plus chemotherapy in ovarian, gastroesophageal, or meta-
static colorectal cancer [17,35,37,38]. Two patients across cohorts A1 and
A3 developed grade 3 gastrointestinal perforations that were considered
by the investigator as possibly related to trebananib treatment. One pa-
tient in cohort A1 died of intestinal perforation, which was rated by
investigators as unrelated to trebananib or PLD administration. No gas-
trointestinal perforations occurred in a phase 2 study of patients with
recurrent ovarian cancer receiving trebananib plus paclitaxel [17]. The
only AEs of gastrointestinal perforation were observed in one patient in
a phase 2 study of trebananib plus FOLFIRI in patientswithmetastatic co-
lorectal cancer and in one patient in a phase 2 study of trebananib plus
cisplatin and capecitabine in patients with gastroesophageal cancer [35,
38]. One patient in an ongoing phase 1b study of patients with ovarian
cancer developed grade 2 female colovaginal ﬁstula [39].
Trebananib at 10 mg/kg or 15 mg/kg plus PLD or topotecan showed
evidence of antitumor activity. The ORRs in the trebananib plus
topotecan cohorts (B1 and B3) appeared lower comparedwith those ob-
served in cohorts A1 and A3. Patients in cohorts B1 and B3 relative to co-
horts A1 and A3 tended to receive a higher number of prior anticancer
therapies. Additionally, almost half of the patients across cohorts B1
and B3 received prior doxorubicin or PLD. Only one patient across co-
horts A1 and A3 received prior topotecan. Any additional conjecture to
explain the ORR differences between those cohorts would be speculative
given that this phase 1b study was not designed to compare efﬁcacy.
There is some indication of a clinical beneﬁt in an ongoing randomized
phase 3 study of patients with platinum-resistant recurrent ovarian can-
cer receiving bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every
3 weeks plus PLD, topotecan, or paclitaxel [40]. Exploratory analyses
from that study suggested median PFS duration of 5.4 months and
5.8 months in the PLD and topotecan cohorts, respectively; ORRs were
18.3% and 22.8%, respectively. The median PFS duration of 7.4 months
and 7.1 months for cohorts A1 and A3, respectively, in the current
study was consistent with results from the TRINOVA-1 study of
trebananib plus paclitaxel in patients with recurrent ovarian cancer. Pa-
tients receiving trebananib 15 mg/kg IVQWplus paclitaxel had amedian
PFS of 7.2 months [36].
The PKof trebananib andPLDor topotecandidnot appear tomarkedly
affect the cotherapy agent. The PK parameters for trebananib at week 5
were similar to those reported in a monotherapy trial [16]. Furthermore,
the concentration–time proﬁles of each chemotherapy agent did not
change after coadministration of trebananib.
Most pharmacodynamic changes appeared time-dependent on
trebananib administration, but were generally minor. Because of the
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Fig. 3. Pharmacokinetic concentration–time proﬁles. Mean (+SD) plasma concentration–time proﬁles of pegylated liposomal doxorubicin (PLD; A), doxorubicinol (B), topotecan (C), and
topotecan lactone (D) at week 1 prior to initiation of trebananib administration and at week 5 following weekly IV infusions of trebananib.
32 I. Vergote et al. / Gynecologic Oncology 135 (2014) 25–33study design, it was not possible to distinguish between a predictive ef-
fect of trebananib and a prognostic effect of baseline VEGF or baseline
Ang2 and PFS. This ﬁnding was an exploratory endpoint of the study
and not corrected formultiplicity of testing. Future studieswould beneﬁt
from a closer examination of such prognostic and predictive relation-
ships by relying on larger samples and more appropriate study designs.
In conclusion, in patientswith recurrent platinum-resistant or partial-
ly platinum-sensitive ovarian cancer, the treatment combinations of thedual Ang1/Ang2 inhibitor trebananib 10 mg/kg or 15 mg/kg IV QW
plus PLD 50 mg/m2 Q4W or topotecan 4 mg/m2 on days 1, 8, and 15 of
a 28-day schedule appeared to have acceptable toxicity proﬁles. Results
suggest antitumor activity across all cohorts. The combination of
trebananib and PLD in patients with recurrent platinum-resistant or
partially platinum-sensitive ovarian cancer is currently being studied
in a phase 3 clinical trial (TRINOVA-2; ClinicalTrials.gov identiﬁer:
NCT01281254).
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